Zasocitinib

Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease. It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile.